Earlier this week, Speaker of the House of Representatives Nancy Pelosi (D-CA) reached an agreement with President Donald Trump on passage of the United States-Mexico-Canada Agreement (USMCA), which if passed into law would replace the defunct and much maligned North American Free Trade Agreement (NAFTA). Not everyone is happy about the latest version of the USMCA agreed upon by the White House and House Democrats, including the U.S. Chamber of Commerce, which continues to support the overall agreement but has great concerns about the new provisions in the latest negotiated agreement between President Trump and Speaker Pelosi, which strikes expanded protection for biologic drugs from the agreement completely. Over the summer, House Democrats vocally opposed granting 10 years of regulatory data protection (RDP) for biologics inventions—an increase from 8 years in Canada and from 5 years in Mexico—arguing it would result in higher drug prices and delayed entry for biosimilars.
Business
- Don’t Get Caught In the Conflict: U.S. Versus Brazilian IP Transfer Pricing Rules
- Identifying the Crucial Qualities of Great IP Managers
- From Research to Market Value: Innovation Value Teams
- Three Key Strategies for Adapting Patent Departments to Agile Innovation Settings
- What Brand Owners and Small Businesses Can Learn from Backcountry.com’s Trademark Enforcement Campaign
Recent Posts
- Don’t Get Caught In the Conflict: U.S. Versus Brazilian IP Transfer Pricing Rules
- Other Barks & Bites, Friday, February 21: Federal Circuit Upholds Damages Limit for Failure to Mark, India Signs IP Accord with U.S. and Copyright Office Announces Fee Increases
- Lessons of Wisdom Following Athena SCOTUS Denial and October 2019 Patent Eligibility Guidance Update
- Bayh-Dole 40: Celebrating the Past, Protecting the Future
- Earth to Google: Here’s Why APIs Need to be Copyrightable